Table 4. Harrell's c-indices and 95% confidence intervals of models derived using the entire population for the prediction of major bleeding, major gastrointestinal bleeding, and intracranial hemorrhage, as applied, unmodified, to various subpopulations for prediction of various outcomes at 1 year.

Model	Population
	Overall	AF (AVERROES, RE-LY)	ESUS (NAVIGATE ESUS)	Coronary and peripheral artery disease (COMPASS)
Major bleed	0.69 (0.68, 0.71)	0.73 (0.71, 0.75)	0.73 (0.70, 0.80)	0.66 (0.65, 0.69)
Major GI bleed	0.75 (0.74, 0.78)	0.76 (0.73, 0.79)	0.73 (0.70, 0.85)	0.75 (0.73, 0.80)
ICH	0.72 (0.70, 0.79)	0.75 (0.70, 0.82)	0.82 (0.78, 0.92)	0.69 (0.66, 0.79)

Abbreviations: AF, atrial fibrillation; AVERROES, Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; COMPASS, Cardiovascular Outcomes for People Using Anticoagulation Strategies; ESUS, embolic stroke of undetermined source; GI, gastrointestinal; ICH, intracranial hemorrhage; NAVIGATE ESUS, New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source; RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy.